NCT07018635

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

An Open-Label Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	INCB161734	Oral; Tablet
DRUG	Itraconazole	Oral; Tablet
DRUG	Rifampin	Oral; Tablet
DRUG	Esomeprazole	Oral; Tablet
DRUG	Famotidine	Oral; Tablet

Timeline

• Start date: 2025-07-16
• Primary completion: 2025-09-29
• Completion: 2025-09-29
• First posted: 2025-06-12
• Last updated: 2025-11-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study